Imagion Biosystems Limited (ASX: IBX) has revealed findings from the completion of the IBI10103 phase I clinical trial, assessing the safety and clinical viability of MagSense® HER2 Imaging Agent (MSH2IA) in tandem with MRI for evaluating axillary lymph node metastasis among HER2+ primary breast cancer patients. The trial effectively reached its primary endpoint, demonstrating the safety and tolerability of the imaging agent.
Notably, the results suggest that trained radiologists could potentially differentiate suspicious lymph nodes infiltrated with metastatic HER2+ cancer from those responding normally to immune reactions. The study enrolled thirteen women diagnosed with HER2+ breast cancer, all of whom received the drug treatment without encountering any safety concerns, toxicity issues, or drug-related adverse events. These promising outcomes pave the way for further exploration of MagSense® HER2 Imaging Agent as a valuable adjunct to MRI for assessing metastasis in breast cancer patients with HER2+ status.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
